Possible effects of treatments durations with Ruxolitinib on inhibiting jak phosphorylation of STAT1 in A549 lung cancer cells

This study explores the effects of different treatment durations of Ruxolitinib on inhibiting JAK phosphorylation of STAT1 in A549 lung cancer cells. The JAK/STAT signaling pathway is critical in lung cancer development and progression. By utilizing western blotting, a STAT luciferase reporter assay, and an MTT viability assay, the study evaluates the impact of Ruxolitinib treatment on STAT1 phosphorylation, STAT activation, and cell viability. Understanding how treatment duration influences JAK/STAT pathway inhibition provides valuable insights for developing targeted therapies in lung cancer. This research contributes to addressing the challenges of lung cancer treatment by exploring the potential of Ruxolitinib as a therapeutic agent.